AI assistant
Quest PharmaTech Inc. — Capital/Financing Update 2023
Jun 9, 2023
44256_rns_2023-06-09_817901b0-9cf5-4d47-bf78-0fb64777ac50.pdf
Capital/Financing Update
Open in viewerOpens in your device viewer
Quest PharmaTech Provides Corporate Update
TSX Venture: QPT
EDMONTON, AB, June 9, 2023 /CNW/ - Quest PharmaTech Inc. (TSXV: QPT) ("Quest" or the "Company") provided the following corporate update today.
Grant of Stock Options
Quest announces the granting of 1,250,000 stock options to 2 Officers, at an exercise price of $0.10 per common share, expiring 5 years from the date of grant, subject to TSX Venture Exchange approval.
About Quest PharmaTech Inc.
Quest PharmaTech Inc is a publicly traded, Canadian based biopharmaceutical company (TSX-V: QPT) developing products to improve the quality of life. The company has a 42.5% ownership interest in OncoQuest Inc. which sold its immunotherapy technology assets to Korea-based OQP Bio Inc. in 2020. Quest also has a 23% ownership interest in OncoVent, a Chinese joint venture developing antibody-based immunotherapeutic products for cancer for the Greater China territory. Quest is also developing proprietary MAb AR 9.6 targeting truncated MUC16 as theranostic agents for cancer. AR 9.6 was licensed from University of Nebraska and currently is in late preclinical stage. To learn more, visit www.questpharmatech.com
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
SOURCE Quest PharmaTech Inc.
View original content: http://www.newswire.ca/en/releases/archive/June2023/09/c2929.html
==> picture [8 x 8] intentionally omitted <==
%SEDAR: 00008400E
For further information: Dr. Madi R. Madiyalakan, CEO, Quest PharmaTech Inc., Tel: (780) 4481400, Email: [email protected]
CO: Quest PharmaTech Inc.
CNW 17:00e 09-JUN-23